RecruitingNCT07165184
Incidence of 107 Lymph Node Metastasis
A Prospective Observational Study of Subcarinal Lymph Node Metastasis in Patients With Esophageal Cancer
Sponsor
Fudan University
Enrollment
1,100 participants
Start Date
Jul 21, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
the study was to document the incidence o subcarinal lymph node metastasis, and the risk factors of metastasis.
Eligibility
Min Age: 20 YearsMax Age: 85 Years
Plain Language Summary
Simplified for easier understanding
This study measures how often esophageal cancer (specifically squamous cell carcinoma of the food pipe) spreads to a specific group of lymph nodes near the main airway (station 107). This knowledge helps surgeons decide which lymph nodes to remove during esophagus surgery.
**You may be eligible if...**
- You have been diagnosed with esophageal squamous cell carcinoma
- Your cancer is staged as T1–T4a (any depth of growth) without distant spread (M0)
- You have no history of other cancers
**You may NOT be eligible if...**
- Your cancer is located in the neck portion of the esophagus
- You are not healthy enough to undergo esophagectomy (removal of part of the esophagus)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERno intervention was applied as observation study
no intervention was applied as observation study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07165184
Related Trials
DESTINY-PANTUMOUR04
NCT0712400017 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994450 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597244 locations
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT067107567 locations
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT028388361 location